Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Metabolic strugGLS after FLT3 inhibition in AML.

Taylor SJ, Steidl U.

Blood. 2018 Apr 12;131(15):1631-1632. doi: 10.1182/blood-2018-03-836338. No abstract available.

PMID:
29650728
2.

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.

Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao3003. doi: 10.1126/scitranslmed.aao3003.

PMID:
29643228
3.

Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCAD.

Escudero S, Zaganjor E, Lee S, Mill CP, Morgan AM, Crawford EB, Chen J, Wales TE, Mourtada R, Luccarelli J, Bird GH, Steidl U, Engen JR, Haigis MC, Opferman JT, Walensky LD.

Mol Cell. 2018 Mar 1;69(5):729-743.e7. doi: 10.1016/j.molcel.2018.02.005.

PMID:
29499131
4.

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.

Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA.

Blood. 2018 Apr 12;131(15):1730-1742. doi: 10.1182/blood-2017-09-807024. Epub 2018 Feb 16.

PMID:
29453291
5.

Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia.

Darbinyan K, Shastri A, Budhathoki A, Helbig D, Snyder R, Pradhan K, Saleh-Esa J, Kornblum NS, Binder AF, Goel S, Janakiram M, Derman O, Gritsman K, Steidl U, Braunschweig I, Verma A, Mantzaris I.

Blood Adv. 2017 Oct 26;1(24):2120-2123. doi: 10.1182/bloodadvances.2017007013. eCollection 2017 Nov 14.

6.

Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.

Anampa J, Haque T, Murakhovskaya I, Wang Y, Bachiashvili K, Papazoglu C, Pradhan K, Steidl UG, Sparano JA, Verma A.

Haematologica. 2018 Mar;103(3):e98-e102. doi: 10.3324/haematol.2017.181941. Epub 2017 Nov 30. No abstract available.

7.

STAT3 inhibition as a therapeutic strategy for leukemia.

Kanna R, Choudhary G, Ramachandra N, Steidl U, Verma A, Shastri A.

Leuk Lymphoma. 2017 Nov 22:1-7. doi: 10.1080/10428194.2017.1397668. [Epub ahead of print]

PMID:
29164994
8.

Pharmacological inhibition of the transcription factor PU.1 in leukemia.

Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U.

J Clin Invest. 2017 Dec 1;127(12):4297-4313. doi: 10.1172/JCI92504. Epub 2017 Oct 30.

9.

Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia.

Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD, Verma A, Steidl U, Gavathiotis E.

Cancer Cell. 2017 Oct 9;32(4):490-505.e10. doi: 10.1016/j.ccell.2017.09.001.

PMID:
29017059
10.

Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways.

Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A, Verma A.

Genome Res. 2017 Nov;27(11):1830-1842. doi: 10.1101/gr.222794.117. Epub 2017 Oct 6.

PMID:
28986391
11.

ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα.

Gonzalez D, Luyten A, Bartholdy B, Zhou Q, Kardosova M, Ebralidze A, Swanson KD, Radomska HS, Zhang P, Kobayashi SS, Welner RS, Levantini E, Steidl U, Chong G, Collombet S, Choi MH, Friedman AD, Scott LM, Alberich-Jorda M, Tenen DG.

J Biol Chem. 2017 Nov 17;292(46):18924-18936. doi: 10.1074/jbc.M117.811109. Epub 2017 Sep 12.

PMID:
28900037
12.

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.

Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.

PMID:
28684528
13.

Efficacy of ALK5 inhibition in myelofibrosis.

Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, Mailloux AW, Zhang L, Wang X, Budhathoki A, Pradhan K, Rapaport F, Wang H, Shao Z, Ren X, Steidl U, Levine RL, Zhao ZJ, Verma A, Epling-Burnette PK.

JCI Insight. 2017 Apr 6;2(7):e90932. doi: 10.1172/jci.insight.90932.

14.

ETO2-GLIS2: A Chimeric Transcription Factor Drives Leukemogenesis through a Neomorphic Transcription Network.

Wheat JC, Steidl U.

Cancer Cell. 2017 Mar 13;31(3):307-308. doi: 10.1016/j.ccell.2017.02.015.

15.

A myeloid tumor suppressor role for NOL3.

Stanley RF, Piszczatowski RT, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U.

J Exp Med. 2017 Mar 6;214(3):753-771. doi: 10.1084/jem.20162089. Epub 2017 Feb 23.

16.

Stem and progenitor cell alterations in myelodysplastic syndromes.

Shastri A, Will B, Steidl U, Verma A.

Blood. 2017 Mar 23;129(12):1586-1594. doi: 10.1182/blood-2016-10-696062. Epub 2017 Feb 3. Review.

17.

DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders.

Sato H, Wheat JC, Steidl U, Ito K.

Front Oncol. 2016 Aug 22;6:187. doi: 10.3389/fonc.2016.00187. eCollection 2016. Review.

18.

Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy.

Carvajal LA, Steidl U.

Cell Stem Cell. 2016 Jul 7;19(1):6-8. doi: 10.1016/j.stem.2016.06.005.

19.

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A.

Cancer Res. 2016 Aug 15;76(16):4841-4849. doi: 10.1158/0008-5472.CAN-15-3062. Epub 2016 Jun 10.

20.

Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans.

Mantzaris I, Yu Y, Msaouel P, Lam AP, Janakiram M, Friedman EW, Steidl U, Verma AK.

Oncotarget. 2016 Oct 18;7(42):67948-67955. doi: 10.18632/oncotarget.8996.

21.

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A.

Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. No abstract available.

PMID:
27125205
22.

Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal.

Pietras EM, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk LV, Zhang S, Lakshminarasimhan R, Chin CP, Techner JM, Will B, Nerlov C, Steidl U, Manz MG, Schroeder T, Passegué E.

Nat Cell Biol. 2016 Jun;18(6):607-18. doi: 10.1038/ncb3346. Epub 2016 Apr 25.

23.

Molecular Mechanism of Mutant CALR-Mediated Transformation.

Stanley RF, Steidl U.

Cancer Discov. 2016 Apr;6(4):344-6. doi: 10.1158/2159-8290.CD-16-0238.

24.

Ectopic DNMT3B expression delays leukemogenesis.

Stanley RF, Steidl U.

Blood. 2016 Mar 24;127(12):1525-6. doi: 10.1182/blood-2016-01-692137.

25.

Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.

Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau MM, Steidl U, List AF, Evans T, Verma A, Wickrema A.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6359-68. doi: 10.1073/pnas.1516394112. Epub 2015 Nov 2.

26.

Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.

Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A.

Leukemia. 2016 Mar;30(3):536-44. doi: 10.1038/leu.2015.297. Epub 2015 Oct 26. Review.

PMID:
26500138
27.

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.

Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U.

Nat Chem Biol. 2015 Nov;11(11):878-86. doi: 10.1038/nchembio.1930. Epub 2015 Oct 5.

28.

Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.

Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Neriah DB, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U.

Nat Med. 2015 Oct;21(10):1172-81. doi: 10.1038/nm.3936. Epub 2015 Sep 7.

29.

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U.

Blood. 2015 Aug 27;126(9):1118-27. doi: 10.1182/blood-2014-12-618801. Epub 2015 Jul 13.

30.

Functionally relevant RNA helicase mutations in familial and sporadic myeloid malignancies.

Antony-Debré I, Steidl U.

Cancer Cell. 2015 May 11;27(5):609-11. doi: 10.1016/j.ccell.2015.04.013.

31.

Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer SD, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine RL.

Cancer Cell. 2015 Apr 13;27(4):502-15. doi: 10.1016/j.ccell.2015.03.009.

32.

IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will B, Wei S, Steidl U, Verma A.

Blood. 2015 May 14;125(20):3144-52. doi: 10.1182/blood-2015-01-621631. Epub 2015 Mar 25. Erratum in: Blood. 2015 Jul 16;126(3):425. Barreryo, Laura [corrected to Barreyro, Laura].

33.

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G.

Leukemia. 2015 Jul;29(7):1458-69. doi: 10.1038/leu.2015.69. Epub 2015 Mar 12. Review.

34.

A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.

Verma A, Steidl U.

Nat Med. 2015 Feb;21(2):113-4. doi: 10.1038/nm.3796. No abstract available.

PMID:
25654599
35.

CDK6, a new target in MLL-driven leukemia.

Antony-Debré I, Steidl U.

Blood. 2014 Jul 3;124(1):5-6. doi: 10.1182/blood-2014-05-572917.

36.

Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.

Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC.

Mol Cancer Ther. 2014 Aug;13(8):1979-90. doi: 10.1158/1535-7163.MCT-13-0963. Epub 2014 Jun 16.

37.

Combinatorial haplo-deficient tumor suppression in 7q-deficient myelodysplastic syndrome and acute myeloid leukemia.

Will B, Steidl U.

Cancer Cell. 2014 May 12;25(5):555-7. doi: 10.1016/j.ccr.2014.04.018. Erratum in: Cancer Cell. 2014 Jun 16;25(6):860.

38.

Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.

Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A.

Leuk Lymphoma. 2014 Dec;55(12):2901-6. doi: 10.3109/10428194.2014.894186. Epub 2014 Mar 20.

PMID:
24650011
39.

Stem cell fate regulation by dynein motor protein Lis1.

Will B, Steidl U.

Nat Genet. 2014 Mar;46(3):217-8. doi: 10.1038/ng.2902.

PMID:
24569235
40.

HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia.

Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat TD, Okoye-Okafor UC, Todorova TI, Greally JM, Levine RL, Melnick A, Verma A, Steidl U.

J Clin Invest. 2014 Mar;124(3):1158-67.

41.

Stem cell origin of myelodysplastic syndromes.

Elias HK, Schinke C, Bhattacharyya S, Will B, Verma A, Steidl U.

Oncogene. 2014 Oct 30;33(44):5139-50. doi: 10.1038/onc.2013.520. Epub 2013 Dec 16. Review.

PMID:
24336326
42.

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.

Pathak S, Roth M, Verma A, Steidl U.

Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1667-75. doi: 10.1517/17425255.2013.858119. Epub 2013 Nov 12. Review.

PMID:
24215532
43.

Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.

Basova P, Pospisil V, Savvulidi F, Burda P, Vargova K, Stanek L, Dluhosova M, Kuzmova E, Jonasova A, Steidl U, Laslo P, Stopka T.

Oncogene. 2014 Sep 25;33(39):4735-45. doi: 10.1038/onc.2013.414. Epub 2013 Oct 14.

PMID:
24121269
44.

HLX in AML: novel prognostic and therapeutic target.

Pandolfi A, Steidl U.

Oncotarget. 2012 Oct 11;3(10):1059-60. Print 2012 Oct. No abstract available.

45.

Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.

Bhattacharyya S, Yu Y, Suzuki M, Campbell N, Mazdo J, Vasanthakumar A, Bhagat TD, Nischal S, Christopeit M, Parekh S, Steidl U, Godley L, Maitra A, Greally JM, Verma A.

Nucleic Acids Res. 2013 Sep;41(16):e157. doi: 10.1093/nar/gkt601. Epub 2013 Jul 16.

46.

Signal transduction inhibitors in treatment of myelodysplastic syndromes.

Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A.

J Hematol Oncol. 2013 Jul 10;6:50. doi: 10.1186/1756-8722-6-50. Review.

47.

Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.

Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U.

Nat Immunol. 2013 May;14(5):437-45. doi: 10.1038/ni.2572. Epub 2013 Apr 7.

48.

Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.

Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB.

J Immunol. 2013 Mar 15;190(6):2966-75. doi: 10.4049/jimmunol.1202493. Epub 2013 Feb 13.

49.

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.

Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A.

Blood. 2013 Apr 11;121(15):2875-81. doi: 10.1182/blood-2011-12-397067. Epub 2013 Feb 6.

50.

Platelet proteome analysis reveals integrin-dependent aggregation defects in patients with myelodysplastic syndromes.

Fröbel J, Cadeddu RP, Hartwig S, Bruns I, Wilk CM, Kündgen A, Fischer JC, Schroeder T, Steidl UG, Germing U, Lehr S, Haas R, Czibere A.

Mol Cell Proteomics. 2013 May;12(5):1272-80. doi: 10.1074/mcp.M112.023168. Epub 2013 Feb 4.

Supplemental Content

Loading ...
Support Center